Indianapolis-based St. Vincent Health will manage operations at Monroe Hospital in Bloomington
under an agreement announced Sept. 4. Adding Monroe gives St. Vincent control of hospitals stretching
from Indianapolis to Bedford and even farther south to Salem and Evansville. St. Vincent owns or operates 22 hospitals around
the state. The only other Indiana hospital with that kind of geographic reach is Indianapolis-based Indiana University Health,
which owns Bloomington Hospital. St. Vincent will oversee quality and safety efforts, physician relations, patient experience,
finance and other functions to increase efficiency and reduce costs. The 32-bed facility, which opened in 2006, is owned by
Alabama-based Medical Properties Trust Inc. Monroe has routinely lost money, including a loss of $13.2 million in 2011, according
to hospital reports to the federal Medicare program, made available by the website AHD.com. Monroe had total patient revenue
last year of $102.4 million. The hospital had been courting potential partners or buyers for at least two years. It entered
discussions not only with St. Vincent, but also with Mishawaka-based Franciscan Alliance and Munster-based Community Healthcare
System.
Nyhart Actuary & Employee Benefits has established its first office on the West Coast with its latest acquisition. Nyhart will add 15 employees by acquiring San
Diego-based Epler Co., a regional actuarial, employee benefits and compensation-strategies firm. Nyhart now has 100 employees,
including 70 at its headquarters in Indianapolis. Financial terms of the deal were not disclosed. The deal gives Nyhart new
expertise on employee compensation, which it hopes will help bolster its pension business for private, church and public plans.
Nyhart serves plans with $15 billion or more in assets, providing fund analysis, advisory services on employee compensation
and retirement benefits, and actuarial work on health care issues. It is the third acquisition Nyhart has made in the last
two years.
Tymora Analytical Operations LLC has received a $150,000 grant from the National Institutes of Health. The
West Lafayette-based company will use the money to develop nanotechnology products that aim to help researchers analyze the
adding of phosphate molecules to proteins in the body, a process that plays a role in cancer, Alzheimer’s disease and
other maladies. Tymora’s leading product would allow researchers to detect multiple changes to proteins in a single
experiment. The 2-year-old company has been funded by a grant from the National Science Foundation, an investment by Purdue’s
Emerging Innovations Fund and winnings from business plan competitions.
Riley Hospital for Children at Indiana University Health will now make its pediatric specialists available
at The South Bend Clinic. Riley specialists in cardiology, diabetes, gastroenterology, neurology and rheumatology will see
patients from throughout the northern Indiana and southern Michigan regions. Riley's hospital facility in downtown Indianapolis
treats children from all over Indiana and beyond the state's borders.

















Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.